Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Professor Tedder tabled a paper on the new generation Abbott and Ortho tests to be discussed at the ninth ACVSB meeting.

  • Read more about Professor Tedder tabled a paper on the new generation Abbott and Ortho tests to be discussed at the ninth ACVSB meeting.

Dr Gunson wrote to regional transfusion directors enclosing an updated report on the comparison study of Abbott and Ortho anti-HCV test kits whilst noting that the study of the new generation tests was proceeding.

  • Read more about Dr Gunson wrote to regional transfusion directors enclosing an updated report on the comparison study of Abbott and Ortho anti-HCV test kits whilst noting that the study of the new generation tests was proceeding.

Dr Gunson produced a paper reporting on the use of the RIBA II confirmatory assay to assess reactive results from the first-generation Ortho and Abbott study.

  • Read more about Dr Gunson produced a paper reporting on the use of the RIBA II confirmatory assay to assess reactive results from the first-generation Ortho and Abbott study.

It was reported in "Blood Bank Week" that Chiron Corporation hoped to have their test to screen blood for non-A non-B Hepatitis available for clinical trials by the end of the year.

  • Read more about It was reported in "Blood Bank Week" that Chiron Corporation hoped to have their test to screen blood for non-A non-B Hepatitis available for clinical trials by the end of the year.

In a minute to Scotland's Deputy Chief Medical Officer Dr Young, Dr McIntyre stated: "Things are moving very fast on the Hepatitis C front" and he anticipated that at the next Advisory Committee on the Virological Safety of Blood meeting it would be decided that "there is no alternative but to recommend the introduction of the test."

  • Read more about In a minute to Scotland's Deputy Chief Medical Officer Dr Young, Dr McIntyre stated: "Things are moving very fast on the Hepatitis C front" and he anticipated that at the next Advisory Committee on the Virological Safety of Blood meeting it would be decided that "there is no alternative but to recommend the introduction of the test."

Dr Mortimer reported on developments in the pilot study, now comparing two further candidate screening tests, from Wellcome and UBI, with results from the Ortho and Abbott test kits.

  • Read more about Dr Mortimer reported on developments in the pilot study, now comparing two further candidate screening tests, from Wellcome and UBI, with results from the Ortho and Abbott test kits.

Professor Cash noted that Dr Gunson conveyed his concern that the Department of Health had still not decided on a start date, and it now seemed the earliest possible date would be May or June 1991.

  • Read more about Professor Cash noted that Dr Gunson conveyed his concern that the Department of Health had still not decided on a start date, and it now seemed the earliest possible date would be May or June 1991.

Professor Cash suggested that the evaluation of second-generation tests might be modified to accommodate the screening programme in Newcastle.

  • Read more about Professor Cash suggested that the evaluation of second-generation tests might be modified to accommodate the screening programme in Newcastle.

Dr Gunson and Dr Perry had argued that there was already sufficient data for ACVSB to recommend to ministers the introduction of a first-generation Hepatitis C donation screening as soon as possible, but their views were rejected.

  • Read more about Dr Gunson and Dr Perry had argued that there was already sufficient data for ACVSB to recommend to ministers the introduction of a first-generation Hepatitis C donation screening as soon as possible, but their views were rejected.

Professor Cash asked for "some idea of the current time schedule to the point of full marketing in the UK for full donation testing."

  • Read more about Professor Cash asked for "some idea of the current time schedule to the point of full marketing in the UK for full donation testing."

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 239
  • Page 240
  • Page 241
  • Page 242
  • Current page 243
  • Page 244
  • Page 245
  • Page 246
  • Page 247
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.